JPRN-jRCT2041200077招募中2 期
A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blinded, Placebo-controlled Design to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
Hirano Takamitsu0 个研究点目标入组 1 人开始时间: 2020年12月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Male and female patients weighing at least 3 kg
- •2.Written informed consent by parent(s)/legal guardian(s) for the pediatric patients and assent by the pediatric patient (depending on local requirements) must be obtained before any study-specific assessment is performed. For adult patients, written informed consent by patients capable of giving consent, or when the patient is not capable of giving consent, by his/her legal/authorized representative (if allowed according to local requirements).
- •3.Patients with genetic diagnosis of NLRC4-GOF, XIAP deficiency, or CDC42 mutation
- •4.Clinical history and investigations consistent with autoinflammation with infantile enterocolitis (AIFEC/NLRC4-GOF), XIAP or CDC42. XIAP patients must have persistent disease or be resistant to escalating therapy.
- •5.At first treatment, evidence of active disease
排除标准
- •1. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or to any of the excipients.
- •2. Signs and symptoms, in the judgment of the investigator, of clinically significant systemic recurrent and/or evidence of active bacterial, fungal, parasitic or viral infections.
- •- COVID-19 specific: If in line with health and governmental authority guidance, it is highly recommended that testing to exclude COVID-19 using PCR or comparable approved methodology be completed within 1 week prior to first dosing.
- •3. Any conditions or significant medical problems, which in the opinion of the investigator places the patient at unacceptable risk for MAS825 therapy
- •4. Previous treatment with anti-rejection and/or immunomodulatory drugs within the past 28 days or 5 half-lives (whichever is the longer) for immunomodulatory therapeutic antibodies (or as listed in the prohibited medications section) prior to MAS825 treatment with thewith the exceptions of glucocorticoids, cyclosporin and targeted binding or blocking therapies.
- •5. A positive HIV test result at Screening. Evidence of prior testing within 3 months is sufficient.A positive HIV test result at Screening. Evidence of prior testing within 3 months is sufficient.
- •6. A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result. Evidence of prior testing within 3 months is sufficient.
- •7. Presence of tuberculosis infection as defined by a positive TB test at Screening. Evidence of prior testing within 3 months is sufficient.
- •8. Live vaccinations within 1 month prior to MAS825 treatment, during the trial, and up to 3 months following the last dose.
- •9. Female patients of child-bearing potential (or Tanner stage 2 or above) who are or might become sexually active, Female patients of child-bearing potential (or Tanner stage 2 or above) who are or might become sexually active, agree to use highly effective contraceptive methods to prevent pregnancy while on MAS825 therapy
研究者
相似试验
招募中
1 期
Study to evaluate the efficacy and safety of MAS825 in patients with autoinflammatory diseases.CTIS2023-504419-34-00ovartis Pharma AG19
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of MAS825 in NLRC4-GOF patientsRC4-GOF, AIFEC (autoinflammation with infantile enterocolitis)MedDRA version: 20.0Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-003596-17-ITOVARTIS PHARMA AG8
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of MAS825 in patients with autoinflammatory diseases.Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.MedDRA version: 23.1Level: PTClassification code 10084306Term: Autoinflammation with infantile enterocolitisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 22.0Level: PTClassification code 10078961Term: Immune-mediated enterocolitisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.0Level: SOCClassification code 10021428Term: Immune system disordersSystem Organ Class: 10021428 - Immune system disordersEUCTR2020-003596-17-CZovartis Pharma AG18
未知
Unknown
Observational Study in Patients With Autosomal Dominant Polycystic Kidney DiseaseAutosomal dominant polycystic kidney disease (ADPKD)JPRN-jRCT1080221699Otsuka Pharmaceutical Dvelopment & Commercialization, Inc.3,000
已完成
4 期
A Multi-center, Longitudinal, Observational Study of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease ProgressioADPKDautosomal polycystic kidney disease10029149NL-OMON36219Otsuka America Pharmaceutical100